Filing Details
- Accession Number:
- 0001209191-18-046313
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-08-10 18:45:05
- Reporting Period:
- 2018-08-09
- Accepted Time:
- 2018-08-10 18:45:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1649167 | Frederic Pla | 301 Penobscot Dr. Redwood City CA 94063 | Chief Bus & Prod Dev Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-08-09 | 1,500 | $27.00 | 41,038 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-08-09 | 800 | $55.52 | 40,238 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-08-09 | 700 | $56.41 | 39,538 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-08-09 | 2,100 | $55.48 | 37,438 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-08-09 | 1,900 | $56.42 | 35,538 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) Holding | Disposition | 2018-08-09 | 1,500 | $0.00 | 1,500 | $27.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
60,200 | 2026-02-16 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 18,734 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 7, 2018.
- Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- Represents weighted average sale price. Actual sale prices ranged from $55.09 to $55.96.
- Represents weighted average sale price. Actual sale prices ranged from $56.12 to $56.91.
- Represents weighted average sale price. Actual sale prices ranged from $56.12 to $56.94.
- The option became exercisable as to 25% of the shares on February 16, 2017, and became exercisable as to 1/48th of the shares each full month thereafter.